Physician

Harry Staszewski, M.D.

According to 2025 Medicare claims, Harry Staszewski, M.D. (NPI: 1366495509) practices hematology/oncology in the Nassau County-Suffolk County, NY market, with the plurality of this provider's patient population coming from Suffolk, NY. This provider's primary affiliated billing organization is NORTH SHORE HEMATOLOGY ONCOLOGY ASSOCIATES PC (NPI: 1396794574; TIN: 112419534) and primary practice location at 11787-0001. Staszewski is affiliated with the ilumed, LLC (ACO ID: D0005) and Vytalize Health 9 ACO LLC (ACO ID: D0313), participating under the REACH model.

Staszewski's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,471 traditional Medicare patients, billed 228,662 HCPCS/CPT codes, and received $3,164,644 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,207 prescription claims across 163 beneficiaries totaling $5,636,486 in drug costs, led by Revlimid (Lenalidomide). 2020 DME data shows 86 claims. Open Payments data shows 1 records totaling $18. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $99,773 to $3,164,644. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,941,239 to $5,636,486. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	400	2,702	$99,773
2016	573	6,167	$167,476
2017	1,039	44,572	$679,441
2018	1,303	106,302	$1,453,440
2019	1,272	193,494	$2,297,829
2020	1,475	313,286	$3,466,499
2021	960	169,963	$1,913,368
2022	862	134,668	$1,784,916
2023	1,238	163,940	$2,099,179
2024	1,471	228,662	$3,164,644

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	114	774	$1,941,239
2016	87	486	$1,454,215
2017	92	347	$651,168
2018	123	660	$1,157,815
2019	132	856	$2,112,885
2020	114	726	$2,187,188
2021	118	645	$2,097,048
2022	137	804	$2,927,435
2023	153	1,100	$4,623,914
2024	163	1,207	$5,636,486

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	11	237	$47,443
2016	N/R	114	$14,558
2017	N/R	36	$724
2018	11	34	$3,806
2019	33	53	$6,613
2020	43	86	$7,050
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	648	1,197	$107
80053	Blood test, comprehensive group of blood chemicals	965	2,135	$10
36415	Insertion of needle into vein for collection of blood sample	1,204	2,994	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	1,107	2,911	$8
83615	Lactate dehydrogenase (enzyme) level	590	1,161	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	62	1,659	$979,799
Ibrance	Palbociclib	30	1,008	$563,389
Jakafi	Ruxolitinib Phosphate	22	660	$375,102
Darzalex Faspro	Daratumumab-Hyaluronidase-Fihj	29	824	$353,124
Aranesp	Darbepoetin Alfa In Polysorbat	96	2,030	$297,663

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$18	Merck Sharp & Dohme LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Harry Staszewski, M.D.?

Tedicare shows public-source Medicare data for Harry Staszewski, M.D. (NPI 1366495509), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Harry Staszewski, M.D. have ACO affiliation data?

Harry Staszewski, M.D. is shown with ACO affiliation data for ilumed, LLC (REACH, ACO ID D0005) and Vytalize Health 9 ACO LLC (REACH, ACO ID D0313).

What billing organization is linked to Harry Staszewski, M.D.?

Harry Staszewski, M.D. is linked to NORTH SHORE HEMATOLOGY ONCOLOGY ASSOCIATES PC (billing NPI 1396794574) in the available physician profile data.

Does Harry Staszewski, M.D. have Open Payments data?

Harry Staszewski, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.